What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?

作者信息

Covino Jean, Hoffman Jennifer

机构信息

At Pace University-Lenox Hill Hospital in New York City, Jean Covino is a professor and Jennifer Hoffman is an associate professor in the PA program. Dr. Covino also practices at Medemerge Family Practice Center in Green Brook, N.J. The authors have disclosed no potential conflicts of interest, financial or otherwise.

出版信息

JAAPA. 2018 Mar;31(3):12-14. doi: 10.1097/01.JAA.0000530303.23280.6c.

DOI:10.1097/01.JAA.0000530303.23280.6c

PMID:29470367

Abstract

New classes of drugs to treat type 2 diabetes are continually being developed and marketed. The FDA has issued guidance to the pharmaceutical industry that newer hypoglycemic agents should not be associated with unacceptable increases in cardiovascular risk. To date, five trials have assessed specific cardiovascular endpoints for these newer agents. Empagliflozin and liraglutide have been found to improve cardiovascular outcomes.

摘要